Relmada Therapeutics is a clinical-stage business that creates therapies for chronic pain. The U.S. District Court has issued a restraining order to Laidlaw and Company and to Matthew Eitner and James Ahern for offering false and misleading materials. A previous lawsuit from Relmada against Messrs and Laidlaw led to the court issued response. Laidlaw is an investment firm that previously assisted Relmada. The principals of Laidlaw led to the U.S. financial regulations being violated, which led to the customer complains and monetary penalties.
Sergio Traversa, the Chief Executive of Relmada is very pleased with the Court recognizing the importance of their request and the issuance of an order. They would prefer the focus of attention would be on Relmada’s products and the development of BuTab. He does not believe that the Company to Laidlaw would be value destructive. He believes that the interests of Laidlaw are different from those of the Relmada stockholders. He will continue to take action and protect his company and the Relmada stockholders.
Laidlaw and Company has over 170 years of banking experience. They focus on international and domestic companies. They have over 150 companies working for them in Europe and the United States. They focus on a strong work ethic and enjoy thinking outside of the box. Laidlaw and Company has the ability to help emerging businesses raise capital through retail sales and gives corporate clients the ability to grow financially.
They are a healthcare driven investment company that focuses on helping senior professionals use their experience with an independent firm. They strive to have a hands-o management team that offers positive solutions. They serve clients on a global basis and continue to grow a positive reputation for themselves.
Original Source: